Clinical Trial Detail

NCT ID NCT01943422
Title Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors John Kirkwood
Indications

melanoma

Therapies

Interferon alpha-2b + Vemurafenib

Age Groups: adult senior

Additional content available in CKB BOOST